Our Research Tax Credit accreditation renewed until 2028
We are proud to announce that we remain an accredited Research Tax Credit (CIR) provider until 2028. This renewal underlines our dedication to supporting pharmaceutical and biotech companies in the analytical phases of their R&D programmes.
What does this mean for you?
The French CIR programme enables innovative companies to claim tax reductions on up to 30% of eligible subcontracted R&D expenditures. As an approved partner, you can integrate our analytical expertise into your CIR-eligible activities, optimising both your development strategy and its financial impact. This renewed accreditation confirms that our scientific standards, processes and operational excellence meet the highest requirements for your R&D contributions.
We are your reference partner for analytical services.
Founded in 1982, we are a European reference CRO for leading pharmaceutical companies and biotechs. We deliver tailored analytical solutions for your most innovative drug candidates, from the design and optimisation of analytical methods to the implementation of robust protocols and the use of advanced technological platforms. Our single-site infrastructure ensures the generation and interpretation of high-quality data required for regulatory submissions to the EMA and FDA.
Our objective? Accelerate the development and time-to-patient of your products
We offer the full range of analytical services required for the pharmaceutical development of innovative drug products: